Table 4.

Results of the main and sensitivity analyses (based on 5,000 bootstrap simulations)

	Incremental costs, € (95% CI)	Incremental effects (95% CI)	Mean ICER/ICUR (95% CI)	Distribution over the incremental cost-effectiveness plane
				NE	NW	SE	SW
Analysis ACTonPainguided vs CG
Cost-effectiveness analysis (treatment response)	6 (−916 to 953)	0.14 (0.08 to 0.2)	45 (−6,671 to 8,260)	50%	–	50%	–
Cost-utility analysis (QALYs based on AQoL-8D)	6 (−916 to 953)	0.01 (0.005 to 0.015)	604 (−92,924 to 114,325)	50%	–	50%	–
Sensitivity analysis (QALYs based on EQ5D-3L)	6 (−916 to 953)	0.014 (0.004 to 0.024)	438 (−69,407 to 122,314)	50%	–	50%	–
Analysis ACTonPainunguided vs CG
Cost-effectiveness analysis (treatment response)	−352 (−1,968 to 1,272)	0.12 (0.006 to 0.232)	ACTonPainunguided dominates CG	32%	1%	66%	1%
Cost-utility analysis (QALYs based on AQoL-8D)	−352 (−1,968 to 1,272)	0.013 (0.002 to 0.024)	ACTonPainunguided dominates CG	32%	1%	66%	1%
Sensitivity analysis (QALYs based on EQ5D-3L)	−352 (−1,968 to 1,272)	0.017 (−0.005 to 0.04)	ACTonPainunguided dominates CG	30%	4%	64%	3%
Analysis ACTonPainguided vs ACTonPainunguided
Cost-effectiveness analysis (treatment response)	388 (−1,416 to 2,185)	0.164 (0.034 to 0.29)	2,374 (−11,097 to 25,276)	65%	–	35%	–
Cost-utility analysis (QALYs based on AQoL-8D)	388 (−1,416 to 2,185)	0.008 (−0.003 to 0.019)	45,993*	60%	5%	33%	2%
Sensitivity analysis (QALYs based on EQ5D-3L)	388 (−1,416 to 2,158)	0.01 (−0.01 to 0.031)	37,327*	53%	12%	31%	4%

CG, waitlist control group; ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-utility ratio; MPI, Pain Interference Scale of the Multidimensional Pain Inventory; NE, northeast quadrant; NW, northwest quadrant; PGIC, Patient Global Impression of Change scale; SE, southeast quadrant; SW, southwest quadrant.

*A dependably accurate 95% CI for this distribution cannot be defined because there is no line through the origin that excludes α/2 of the distribution.⁷³